Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc. (AMPH)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Amphastar is a bio-pharmaceutical company focused on developing, manufacturing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredients (API). The company operates two reportable segments: Finished Pharmaceutical Products and API.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Total Net Revenues | $182,394 | $145,712 | $354,230 | $285,734 |
| Gross Profit | $95,166 | $72,738 | $185,266 | $146,578 |
| Gross Margin | 52.2% | 50.0% | 52.3% | 51.3% |
| Net Income | $37,949 | $26,124 | $81,126 | $52,156 |
| Diluted EPS | $0.73 | $0.49 | $1.54 | $0.99 |
| Operating Cash Flow (6M) | $124,400 (2024) vs $95,305 (2023) | |||
| Cash & Equivalents (Balance Sheet) | $189,619 (June 30, 2024) | |||
| Total Debt (Gross) | $599,741 (June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased 25% in Q2 2024 and 24% for the six months ended June 30, 2024, compared to the prior year periods. This growth was primarily driven by the inclusion of BAQSIMI® sales following the assumption of distribution responsibilities from Eli Lilly in Q1 2024.
- Product Performance:
- BAQSIMI®: Generated $30.9 million in Q2 2024 product revenue (previously reported as "Other revenues" or net basis). Six-month revenue was $44.7 million.
- Epinephrine: Sales increased 67% in Q2 due to higher unit volumes driven by competitor shortages.
- Primatene MIST®: Sales increased 38% in Q2 due to higher unit volumes.
- Declines: Sales of Phytonadione (-42%), Enoxaparin (-33%), and Lidocaine (-9%) decreased due to lower unit volumes as competitors returned to historical distribution levels.
- Profitability: Net income increased 45% in Q2 and 56% for the six-month period. Gross margins improved to 52% in Q2 2024 from 50% in Q2 2023, aided by the mix shift toward higher-margin products like BAQSIMI® and Primatene MIST®.
- Interest Expense: Interest expense increased significantly (139% in Q2) due to the Term Loan used to finance the BAQSIMI® acquisition and the 2029 Convertible Notes.
Guidance, Outlook, and Risks
- BAQSIMI® Transition: The company assumed distribution for BAQSIMI® in the U.S. (approx. 80% of global revenue) and certain European countries in Q1 2024. Remaining territories will be transitioned on a country-by-country basis throughout 2024. Future revenue recognition will shift from a net basis (royalty-like) to gross basis as distribution is assumed.
- Product Launches: The FDA approved Albuterol Sulfate Inhalation Aerosol in May 2024, with a planned launch in Q3 2024. The company plans to relaunch Medroxyprogesterone (MPA) in H2 2024 after qualifying its own API manufacturing.
- API Segment Outlook: API sales are expected to remain lower than historical levels for the next two years as the largest customer, MannKind, qualifies the company's upgraded Recombinant Human Insulin (RHI).
- Capital Allocation: The Board authorized a $50.0 million increase to the share buyback program in June 2024. $77.0 million remains available under the program.
- Risks and Contingencies:
- Litigation: A former employee filed a class action complaint regarding wage and hour violations (June 2024). Teva Pharmaceuticals filed a patent infringement lawsuit regarding Amphastar's Albuterol Sulfate ANDA (July 2024).
- Contingent Consideration: The company may owe up to $575.0 million in milestone payments related to the BAQSIMI® acquisition based on net sales targets. No milestones have been triggered as of June 30, 2024.
- Supply Chain: The company relies on single-source suppliers for certain raw materials and APIs, creating potential disruption risks.
Key Investor Verification Points
- BAQSIMI® Revenue Recognition: Verify the timeline for assuming distribution in remaining international territories to understand the transition from net to gross revenue reporting.
- API Customer Qualification: Monitor the progress of MannKind's qualification of the upgraded RHI, as this is a key driver for future API segment recovery.
- Debt Obligations: Review the terms of the 2029 Convertible Notes ($345M) and the Wells Fargo Term Loan ($250M), noting the increased interest expense impact on future earnings.
- Product Pipeline: Track the commercial launch of Albuterol Sulfate and the relaunch of MPA in the second half of 2024.
- Litigation Exposure: Assess the potential financial impact of the pending class action employment lawsuit and the patent infringement suit filed by Teva.